Achmea Investment Management B.V. Cuts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Achmea Investment Management B.V. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 85.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,816 shares of the company's stock after selling 15,974 shares during the period. Achmea Investment Management B.V.'s holdings in IDEXX Laboratories were worth $1,164,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of IDXX. Aptus Capital Advisors LLC lifted its holdings in IDEXX Laboratories by 19.4% during the 3rd quarter. Aptus Capital Advisors LLC now owns 629 shares of the company's stock valued at $318,000 after buying an additional 102 shares in the last quarter. Huntington National Bank lifted its position in shares of IDEXX Laboratories by 1.1% in the 3rd quarter. Huntington National Bank now owns 3,979 shares of the company's stock worth $2,010,000 after purchasing an additional 42 shares during the period. Impax Asset Management Group plc boosted its stake in shares of IDEXX Laboratories by 14.7% during the third quarter. Impax Asset Management Group plc now owns 8,655 shares of the company's stock valued at $4,373,000 after purchasing an additional 1,110 shares in the last quarter. CIBC Asset Management Inc increased its holdings in IDEXX Laboratories by 5.5% during the third quarter. CIBC Asset Management Inc now owns 25,578 shares of the company's stock valued at $12,923,000 after buying an additional 1,338 shares during the period. Finally, Empirical Finance LLC increased its holdings in IDEXX Laboratories by 2.3% during the third quarter. Empirical Finance LLC now owns 2,887 shares of the company's stock valued at $1,459,000 after buying an additional 65 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IDXX shares. Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target for the company. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded up $2.63 on Wednesday, hitting $422.15. 463,314 shares of the company's stock traded hands, compared to its average volume of 548,742. The firm's 50-day moving average price is $437.74 and its two-hundred day moving average price is $445.87. The firm has a market capitalization of $34.33 billion, a PE ratio of 39.56, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.